Il 12 23 Inhibitor denied as not FDA-approved for this use by Cigna?

Cigna requires prior authorization for ustekinumab (Stelara and biosimilars) and the same criteria apply across the IL-12/23 inhibitor class. The SC formulation is covered for Crohn's disease (CD), plaque psoriasis (PsO), psoriatic arthritis (PsA), and ulcerative colitis (UC), while the IV formulation is covered for CD and UC. Prior authorization is required for benefit coverage of ustekinumab intravenous, and approval is recommended only for those who meet the Criteria and Dosing for the listed indications. Initial therapy is approved for 6 months if criteria are met; continuation/re-authorization is approved for 1 year if the patient has been established on the drug for at least 3–6 months and continues to respond. The medication must be prescribed by or in consultation with a specialist in the condition being treated, and certain approvals are limited to 30 days when that is an adequate duration. Concurrent use with another biologic or with a targeted synthetic oral small molecule drug used for an inflammatory condition is not allowed because combination therapy is generally not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy , though conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) are not excluded. Through the Preferred Specialty Management program, the patient is required to meet the standard PA criteria and to try ALL of the Preferred Products prior to approval of a Non-Preferred Product. Pediatric dosing for PsA/PsO follows weight-based limits: pediatric patients ≥12 years weighing 60–100 kg receive 45 mg SC at Week 0, Week 4, then Q12W; those weighing <60 kg receive 90 mg SC at Week 0, Week 4, then Q12W.

- For step-therapy denials in IBD: AGA Clinical Guidelines on the Management of Moderate-to-Severe Ulcerative Colitis and Crohn's Disease support ustekinumab as a first-line biologic option, particularly in TNF-naïve patients; the UNITI-1, UNITI-2, IM-UNITI, and UNIFI pivotal trials demonstrated efficacy that does not require failure of every preferred product if medically inappropriate. - For psoriasis/PsA step-therapy denials: AAD-NPF Joint Guidelines (2019) and ACR/NPF PsA guidelines list ustekinumab as a recommended biologic; cite PHOENIX 1 & 2 (PsO) and PSUMMIT 1 & 2 (PsA) showing durable PASI 75 and ACR20 responses, supporting medical necessity when TNF inhibitors are contraindicated (e.g., demyelinating disease, CHF, latent TB risk). - For combination-therapy denials: cite that conventional synthetic DMARDs (methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) are NOT excluded from concurrent use , so co-prescription with MTX should not trigger denial. - For specialist-prescriber denials: provide attestation from a rheumatologist/GI/derm or documented consult note, satisfying the requirement that the medication be prescribed by or in consultation with a specialist . - For non-FDA indication denials in AS/nr-axSpA: cite the TOPAS open-label study which showed 65% of patients (95% CI: 41%, 85%) achieved an ASAS40 response at Week 24 , supporting off-label medical necessity when ACR/SPARTAN-recommended TNFi and IL-17 options have failed or are contraindicated. - For continuation/reauthorization denials: submit objective response data (PASI improvement, Mayo/CDAI reduction, HBI, joint counts) showing the patient meets the established-therapy criterion of established on the requested drug for at least 3 months . - For non-preferred biosimilar denials on Employer/IFP plans: request a formulary exception citing significant allergy/intolerance to inactive ingredients in preferred products, per documentation supporting that formulation differences in inactive ingredients would result in a significant allergy .

## Why Cigna Issues "Not FDA-Approved" Denials for IL-12/23 Inhibitors

A "not FDA-approved" denial from Cigna typically means one of two things: (1) the specific IL-12/23 inhibitor prescribed is being used for a diagnosis or patient population not listed in the FDA-approved labeling (an "off-label" use), or (2) Cigna's system has a coding or coverage policy mismatch and the use is actually on-label. Identifying which situation applies is the first step before filing.

Off-label use of a biologic is not automatically uncovered — many plans are required to cover off-label uses that are supported by recognized compendia (such as those referenced in NCCN guidelines or other major medical compendia recognized by CMS), particularly for oncology, and the same principle often applies to other therapeutic areas when there is a strong evidence base.

## Your Federal Appeal Rights

• Internal appeal: Under ACA §2719 and ERISA §503, you must first exhaust internal appeals. Respond in writing to every reason given in the denial letter within the deadline stated (verify with your plan documents).
• External review: After an adverse internal determination, independent external review is available within approximately four months of the final internal denial decision. An IRO not affiliated with Cigna evaluates whether the denial was consistent with the plan terms and applicable law.
• Expedited option: If your health would be seriously jeopardized by a standard-timeline review, request expedited processing.

## What to Gather Before You File

1. Confirm whether use is on-label or off-label: Pull the current FDA-approved prescribing information for the exact IL-12/23 inhibitor and confirm the patient's diagnosis and any relevant patient-population criteria against the labeled indications. If it is on-label, the denial may be an administrative error. 2. If off-label: Identify whether the use appears in a recognized major medical compendium or in published peer-reviewed literature. Ask the prescriber to identify the relevant guideline organization's recommendation (e.g., the applicable specialty society guideline). 3. Prescriber medical-necessity letter: The prescriber should explain, citing current professional society guidance, why this specific mechanism is appropriate for this patient's diagnosis even if outside the exact label language. 4. Diagnosis and severity documentation: Specialist notes, objective clinical findings, and documented disease progression or inadequate response to alternatives. 5. Prior-treatment history: Dated record of all therapies previously tried with outcomes.

## Criteria-Mapping Structure

When arguing for coverage of an off-label use, your appeal should directly address the standard Cigna uses for off-label coverage:

| Cigna Off-Label Coverage Requirement | Your Documentation | |---|---| | Use supported by recognized compendium or peer-reviewed evidence | [Cite guideline organization and prescriber letter] | | Diagnosis confirmed | [Chart reference] | | Standard on-label therapies tried or contraindicated | [List with dates] | | Prescriber rationale on file | [Letter date and author] |

If the denial is actually an on-label use, lead with that argument and attach the FDA label highlighting the relevant indication.